
The MCE 1K Drug Fragment Library consists of 1,168 drug fragments. These drug fragments are derived from 2,946 FDA-approved drug molecules, and fragments from one drug can appear in other drugs, so these fragments are somewhat correlated with good PK/PD properties. Fragment-based screening can reserve enough chemical space for subsequent structural optimization. This compound library is an essential tool for drug screening based on FBDD (Fragment-Based Drug Discovery).
For pre-dissolved solutions, 10 mM for compounds with the solubility not lower than 10 mM, and 2 mM for compounds with solubility between 2 mM and 10 mM.
• These fragments are derived from 2,946 FDA-approved drug molecules by BRICS and Recap algorithm and the simple fragment were removed.
• More than 600 fragments compatible with “Rule of three”, with multiple characteristics such as the molecular weight <300, the number of hydrogen bond donors and acceptors ≤3, the number of rotatable bonds ≤ 3, and cLogP <3.
• Provide a compound library based on fragment derivation and custom synthesis services, aiming to reduce your synthesis costs and shorten research and development time.
• NMR and HPLC validated to ensure high purity and quality.
• These fragments are derived from 2,946 FDA-approved drug molecules by BRICS and Recap algorithm and the simple fragment were removed.
• More than 600 fragments compatible with “Rule of three”, with multiple characteristics such as the molecular weight <300, the number of hydrogen bond donors and acceptors ≤3, the number of rotatable bonds ≤ 3, and cLogP <3.
• Provide a compound library based on fragment derivation and custom synthesis services, aiming to reduce your synthesis costs and shorten research and development time.
• NMR and HPLC validated to ensure high purity and quality.